Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: A nationwide discovery cohort

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Myeloproliferative and lymphoproliferative malignancies occurring in the same patient : A nationwide discovery cohort. / Holst, Johanne M.; Plesner, Trine L.; Pedersen, Martin B.; Frederiksen, Henrik; Møller, Michael B.; Clausen, Michael R.; Hansen, Marcus C.; Hamilton-Dutoit, Stephen Jacques; Nørgaard, Peter; Johansen, Preben; Eberlein, Tobias Ramm; Mortensen, Bo K.; Mathiasen, Gustav; Øvlisen, Andreas; Wang, Rui; Wang, Chao; Zhang, Weiwei; Ommen, Hans Beier; Stentoft, Jesper; Ludvigsen, Maja; Tam, Wayne; Chan, Wing C.; Inghirami, Giorgio; d'Amore, Francesco.

In: Haematologica, Vol. 105, No. 10, 2020, p. 2432-2439.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Holst, JM, Plesner, TL, Pedersen, MB, Frederiksen, H, Møller, MB, Clausen, MR, Hansen, MC, Hamilton-Dutoit, SJ, Nørgaard, P, Johansen, P, Eberlein, TR, Mortensen, BK, Mathiasen, G, Øvlisen, A, Wang, R, Wang, C, Zhang, W, Ommen, HB, Stentoft, J, Ludvigsen, M, Tam, W, Chan, WC, Inghirami, G & d'Amore, F 2020, 'Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: A nationwide discovery cohort', Haematologica, vol. 105, no. 10, pp. 2432-2439. https://doi.org/10.3324/haematol.2019.225839

APA

Holst, J. M., Plesner, T. L., Pedersen, M. B., Frederiksen, H., Møller, M. B., Clausen, M. R., Hansen, M. C., Hamilton-Dutoit, S. J., Nørgaard, P., Johansen, P., Eberlein, T. R., Mortensen, B. K., Mathiasen, G., Øvlisen, A., Wang, R., Wang, C., Zhang, W., Ommen, H. B., Stentoft, J., ... d'Amore, F. (2020). Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: A nationwide discovery cohort. Haematologica, 105(10), 2432-2439. https://doi.org/10.3324/haematol.2019.225839

Vancouver

Holst JM, Plesner TL, Pedersen MB, Frederiksen H, Møller MB, Clausen MR et al. Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: A nationwide discovery cohort. Haematologica. 2020;105(10):2432-2439. https://doi.org/10.3324/haematol.2019.225839

Author

Holst, Johanne M. ; Plesner, Trine L. ; Pedersen, Martin B. ; Frederiksen, Henrik ; Møller, Michael B. ; Clausen, Michael R. ; Hansen, Marcus C. ; Hamilton-Dutoit, Stephen Jacques ; Nørgaard, Peter ; Johansen, Preben ; Eberlein, Tobias Ramm ; Mortensen, Bo K. ; Mathiasen, Gustav ; Øvlisen, Andreas ; Wang, Rui ; Wang, Chao ; Zhang, Weiwei ; Ommen, Hans Beier ; Stentoft, Jesper ; Ludvigsen, Maja ; Tam, Wayne ; Chan, Wing C. ; Inghirami, Giorgio ; d'Amore, Francesco. / Myeloproliferative and lymphoproliferative malignancies occurring in the same patient : A nationwide discovery cohort. In: Haematologica. 2020 ; Vol. 105, No. 10. pp. 2432-2439.

Bibtex

@article{1f2f9c670d08426e90e0e8cef635cf67,
title = "Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: A nationwide discovery cohort",
abstract = "Myeloid and lymphoid malignancies are postulated to have distinct pathogenic mechanisms. The recent observation that patients with a myeloproliferative neoplasm have an increased risk of developing lymphoproliferative malignancies has challenged this assumption. We collected a nationwide cohort of patients with both malignancies. Patients diagnosed between 1990 and 2015 were identified through the national Danish Pathology Registry. We identified 599 patients with a myeloproliferative neoplasm and a concomitant or subsequent diagnosis of lymphoma. Histopathological review of the diagnostic samples from each patient led to a final cohort of 97 individuals with confirmed dual diagnoses of myeloproliferative neoplasm and lymphoma. The age range at diagnosis of these individuals was 19-94 years (median: 71 years). To avoid the inclusion of cases of therapy-induced myeloproliferative neoplasm occurring in patients previously treated for lymphoma, only patients with myeloproliferative neoplasm diagnosed unequivocally before the development of lymphoma were included. The average time interval between the diagnoses of the two malignancies was 1.5 years. In the majority of patients (90%) both diagnoses were established within 5 years of each other. Among the lymphoma entities, the frequency of peripheral T-cell lymphomas was markedly increased. Interestingly, all but one of the T-cell lymphomas were of angioimmunoblastic type. These findings suggest that a myeloproliferative neoplasm and lymphoproliferative malignancy developing in the same patient may have common pathogenic events, possibly already at the progenitor level. We believe that the molecular characterization of the newly developed biorepository will help to highlight the mechanisms driving the genesis and clonal evolution of these hematopoietic malignancies.",
author = "Holst, {Johanne M.} and Plesner, {Trine L.} and Pedersen, {Martin B.} and Henrik Frederiksen and M{\o}ller, {Michael B.} and Clausen, {Michael R.} and Hansen, {Marcus C.} and Hamilton-Dutoit, {Stephen Jacques} and Peter N{\o}rgaard and Preben Johansen and Eberlein, {Tobias Ramm} and Mortensen, {Bo K.} and Gustav Mathiasen and Andreas {\O}vlisen and Rui Wang and Chao Wang and Weiwei Zhang and Ommen, {Hans Beier} and Jesper Stentoft and Maja Ludvigsen and Wayne Tam and Chan, {Wing C.} and Giorgio Inghirami and Francesco d'Amore",
year = "2020",
doi = "10.3324/haematol.2019.225839",
language = "English",
volume = "105",
pages = "2432--2439",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "10",

}

RIS

TY - JOUR

T1 - Myeloproliferative and lymphoproliferative malignancies occurring in the same patient

T2 - A nationwide discovery cohort

AU - Holst, Johanne M.

AU - Plesner, Trine L.

AU - Pedersen, Martin B.

AU - Frederiksen, Henrik

AU - Møller, Michael B.

AU - Clausen, Michael R.

AU - Hansen, Marcus C.

AU - Hamilton-Dutoit, Stephen Jacques

AU - Nørgaard, Peter

AU - Johansen, Preben

AU - Eberlein, Tobias Ramm

AU - Mortensen, Bo K.

AU - Mathiasen, Gustav

AU - Øvlisen, Andreas

AU - Wang, Rui

AU - Wang, Chao

AU - Zhang, Weiwei

AU - Ommen, Hans Beier

AU - Stentoft, Jesper

AU - Ludvigsen, Maja

AU - Tam, Wayne

AU - Chan, Wing C.

AU - Inghirami, Giorgio

AU - d'Amore, Francesco

PY - 2020

Y1 - 2020

N2 - Myeloid and lymphoid malignancies are postulated to have distinct pathogenic mechanisms. The recent observation that patients with a myeloproliferative neoplasm have an increased risk of developing lymphoproliferative malignancies has challenged this assumption. We collected a nationwide cohort of patients with both malignancies. Patients diagnosed between 1990 and 2015 were identified through the national Danish Pathology Registry. We identified 599 patients with a myeloproliferative neoplasm and a concomitant or subsequent diagnosis of lymphoma. Histopathological review of the diagnostic samples from each patient led to a final cohort of 97 individuals with confirmed dual diagnoses of myeloproliferative neoplasm and lymphoma. The age range at diagnosis of these individuals was 19-94 years (median: 71 years). To avoid the inclusion of cases of therapy-induced myeloproliferative neoplasm occurring in patients previously treated for lymphoma, only patients with myeloproliferative neoplasm diagnosed unequivocally before the development of lymphoma were included. The average time interval between the diagnoses of the two malignancies was 1.5 years. In the majority of patients (90%) both diagnoses were established within 5 years of each other. Among the lymphoma entities, the frequency of peripheral T-cell lymphomas was markedly increased. Interestingly, all but one of the T-cell lymphomas were of angioimmunoblastic type. These findings suggest that a myeloproliferative neoplasm and lymphoproliferative malignancy developing in the same patient may have common pathogenic events, possibly already at the progenitor level. We believe that the molecular characterization of the newly developed biorepository will help to highlight the mechanisms driving the genesis and clonal evolution of these hematopoietic malignancies.

AB - Myeloid and lymphoid malignancies are postulated to have distinct pathogenic mechanisms. The recent observation that patients with a myeloproliferative neoplasm have an increased risk of developing lymphoproliferative malignancies has challenged this assumption. We collected a nationwide cohort of patients with both malignancies. Patients diagnosed between 1990 and 2015 were identified through the national Danish Pathology Registry. We identified 599 patients with a myeloproliferative neoplasm and a concomitant or subsequent diagnosis of lymphoma. Histopathological review of the diagnostic samples from each patient led to a final cohort of 97 individuals with confirmed dual diagnoses of myeloproliferative neoplasm and lymphoma. The age range at diagnosis of these individuals was 19-94 years (median: 71 years). To avoid the inclusion of cases of therapy-induced myeloproliferative neoplasm occurring in patients previously treated for lymphoma, only patients with myeloproliferative neoplasm diagnosed unequivocally before the development of lymphoma were included. The average time interval between the diagnoses of the two malignancies was 1.5 years. In the majority of patients (90%) both diagnoses were established within 5 years of each other. Among the lymphoma entities, the frequency of peripheral T-cell lymphomas was markedly increased. Interestingly, all but one of the T-cell lymphomas were of angioimmunoblastic type. These findings suggest that a myeloproliferative neoplasm and lymphoproliferative malignancy developing in the same patient may have common pathogenic events, possibly already at the progenitor level. We believe that the molecular characterization of the newly developed biorepository will help to highlight the mechanisms driving the genesis and clonal evolution of these hematopoietic malignancies.

U2 - 10.3324/haematol.2019.225839

DO - 10.3324/haematol.2019.225839

M3 - Journal article

C2 - 33054083

AN - SCOPUS:85092239455

VL - 105

SP - 2432

EP - 2439

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 10

ER -

ID: 256164686